Related Experiment Videos
Affective disorders and tardive dyskinesia.
1Psychiatry Service, V.A. Medical Center, Portland, OR 97207.
L'Encephale
|September 1, 1988
Summary
Mood disorders increase the risk of developing tardive dyskinesia (TD), especially with brief neuroleptic exposure. Treatment prioritizes psychiatric diagnosis, with time often being the best approach for TD management.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Mood disorders, particularly depression, are identified as a significant risk factor for tardive dyskinesia (TD).
- TD onset can occur after short-term exposure to low-to-moderate doses of neuroleptics in patients with mood disorders.
- The precise mechanisms linking mood disorders to increased TD vulnerability remain unclear.
Purpose of the Study:
- To explore the relationship between mood disorders and tardive dyskinesia.
- To identify patient and treatment factors influencing TD risk in this population.
- To discuss treatment and prevention strategies for TD in patients with mood disorders.
Main Methods:
- Review of evidence from multiple studies.
- Analysis of patient and treatment factors.
- Discussion of proposed pathomechanisms and clinical management.
Main Results:
- Mood disorders are a risk factor for TD, with specific patient and treatment factors identified.
- Hypothesized mechanisms involve monoamine activity during mood changes and potential drug interactions.
- Treating TD in patients with mood disorders presents challenges, often requiring prioritization of psychiatric diagnosis.
Conclusions:
- Preventing TD should be the highest priority in managing mood disorders.
- Neuroleptic use should be limited in duration and dose, reserved for acute symptoms or treatment-resistant mood episodes.
- While time may be the most effective treatment for TD, lithium and antidepressants may offer benefits for both mood disorders and TD in select patients.